Table of contents

• JOURNAL CONTENT
• JOURNAL PRACTICES
• ORGANIZATION
• BUSINESS PRACTICES

JOURNAL CONTENT

1. Name of Journal

The official journal title is Chronobiology in Medicine (CIM). The abbreviated title is Chronobiol Med.

2. Website

The URL of official journal web site is https://www.chronobiologyinmedicine.org.

The CIM website proves that it is committed to high ethical and professional standards. It does not contain erroneous information, including any attempt to mimic another journal/publisher’s website.

1) Aims and scope: CIM publishes research articles dealing with the circadian rhythms in various medical fields and clinical sleep medicine. The CIM covers various biological rhythm studies, including sleep and wakefulness, in various medical areas, basic sciences and social sciences. Topics on the clinical sleep disorders such as sleep disordered breathing and insomnia influencing on the circadian rhythm disturbances will be considered for publication.

2) Readership: CIM is primarily for physicians, psychiatrists, neurologists, sleep medicine specialists, basic scientists, and social scientists.

3) Types of manuscripts
CIM publishes Original Article, Review Article, Mini-Review, Brief Report, Editorial, Perspective, and Correspondences. All submitted manuscripts should be original and should not be considered by other scientific journals for publication at the same time. There should be no plagiarism or duplicate publication in the submitted manuscript. The fraudulent data should not be added to the manuscript. Any part of the accepted manuscript should not be duplicated in any other scientific journal without the permission of the Editorial Board. Secondary publication of material published in other journals or online may be justifiable and beneficial, especially when intended to disseminate important information to the widest possible audience (e.g., guidelines produced by government agencies and professional organizations in the same or a different language). Secondary publication for various other reasons may also be justifiable provided the conditions of the International Committee of Medical Journal Editors (ICMJE) Recommendations are met (https://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/overlapping-publications.html#four).

4) Authorship criteria
All persons designated as authors should qualify for authorship. Each author should have participated sufficiently in the work to take public responsibility for the content. According to criteria formulated by the ICMJE, authorship credit should be based on the following 4 criteria (https://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html): 1) substantial contributions to conception and design or analysis and interpretation of data, AND 2) drafting the article or revising it critically for important intellectual content, AND 3) final approval of the version to be published; AND 4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All these 4 conditions must be met. Participation solely in the acquisition of funding or the collection of data does not justify authorship. All other contributors who do not meet these criteria for authorship should be noted in the Acknowledgments section. CIM does not consider people thanked in the Acknowledgements or listed as members of a study group on whose behalf a paper is submitted to be authors. CIM does accept notice of equal contribution for the first author when the study was clearly performed by co-first authors. After the initial submission of a manuscript, any changes whatsoever in authorship (adding author(s), deleting author(s), or re-arranging the order of authors) must be explained by a letter to the editor from the authors concerned. This letter must be signed by all authors of the paper. But after publication, CIM does not correct authorship unless a mistake has been made by the editorial staff. Copyright assignment must also be completed by every author.
Corresponding author(s): One of the authors should be designated to receive correspondence and proofs, and the appropriate address indicated. This author(s) must take primary responsibility for communication with the journal during the manuscript submission, peer-review, and publication process. The corresponding author typically ensures that all the journal’s administrative requirements, such as providing details of authorship, ethics committee approval, clinical trial registration documentation, and disclosures of relationships and activities are properly completed and reported, although these duties may be delegated to one or more co-authors. The corresponding author should be available throughout the submission and peer-review process to respond to editorial queries in a timely way, and should be available after publication to respond to critiques of the work and cooperate with any requests from the journal for data or additional information should questions about the paper arise after publication.

5) eISSN: 2635-9162

3. Publishing schedule

CIM is published on the last day of March, June, September, and December.

4. Archiving

Full text of CIM has been archived in National Library of Korea (https://www.nl.go.kr). Authors are permitted to self-archive the submitted version (preprint), accepted version (peer-reviewed), and publisher's version/PDF of the article at any time in their institutional repository or any non-profit repositories. CIM provides the electronic backup and preservation of access to the journal content in the event the journal is no longer published by archiving in National Library of Korea.

5. Copyright

The copyright of the whole content of papers published in the Journal belongs to the Korean Academy of Sleep Medicine (KASMED) and all authors should sign the copyright transfer form (https://submit.chronobiologyinmedicine.org/) after when their manuscript is submitted.

6. Licensing

CIM is an open access journal distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. For any commercial use of materials in CIM, permission must be obtained from the Korean Academy of Sleep Medicine (chronobiologyinmedicine@gmail.com).

JOURNAL PRACTICES

7. Publication Ethics and Related Editorial Policies

1) Authorship and contributorship
All persons designated as authors should qualify for authorship. Each author should have participated sufficiently in the work to take public responsibility for the content. According to criteria formulated by the ICMJE, authorship credit should be based on the following 4 criteria (https://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html): 1) substantial contributions to conception and design or analysis and interpretation of data, AND 2) drafting the article or revising it critically for important intellectual content, AND 3) final approval of the version to be published; AND 4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All these 4 conditions must be met. Participation solely in the acquisition of funding or the collection of data does not justify authorship. All other contributors who do not meet these criteria for authorship should be noted in the Acknowledgments section. CIM does not consider people thanked in the Acknowledgements or listed as members of a study group on whose behalf a paper is submitted to be authors. CIM does accept notice of equal contribution for the first author when the study was clearly performed by co-first authors. After the initial submission of a manuscript, any changes whatsoever in authorship (adding author(s), deleting author(s), or re-arranging the order of authors) must be explained by a letter to the editor from the authors concerned. This letter must be signed by all authors of the paper. But after publication, CIM does not correct authorship unless a mistake has been made by the editorial staff. Copyright assignment must also be completed by every author.
Corresponding author(s): One of the authors should be designated to receive correspondence and proofs, and the appropriate address indicated. This author(s) must take primary responsibility for communication with the journal during the manuscript submission, peer-review, and publication process. The corresponding author typically ensures that all the journal’s administrative requirements, such as providing details of authorship, ethics committee approval, clinical trial registration documentation, and disclosures of relationships and activities are properly completed and reported, although these duties may be delegated to one or more co-authors. The corresponding author should be available throughout the submission and peer-review process to respond to editorial queries in a timely way, and should be available after publication to respond to critiques of the work and cooperate with any requests from the journal for data or additional information should questions about the paper arise after publication.

2) Complaints and appeals
Submitters, authors, reviewers, and readers may register complaints and appeals in a variety of cases as follows: falsification, fabrication, plagiarism, duplicate publication, authorship dispute, conflict of interest, ethical treatment of animals, informed consent, bias or unfair/inappropriate competitive acts, copyright, stolen data, defamation, and legal problem. If any individuals or institutions want to inform the cases, they can send a letter to editor via the editorial office (editor@chronobiologyinmedicine.org). For the complaints or appeals, please provide concrete data with answers to all factual questions (who, when, where, what, how, why). The editorial committee is responsible for handling and resolving complaints and appeals.

3) Allegations of research misconduct
When the journal faces suspected cases of research and publication misconduct, such as plagiarism, citation manipulation, data falsification/fabrication, a reviewer who has appropriated an author’s idea or data, and complaints against editors, with a submitted manuscript, the discussion and decision on the suspected cases are done by the Editorial Board. CIM will follow the guidelines of the Committee on Publication Ethics (COPE, https://publicationethics.org/) for settlement of any misconduct.

4) Disclosure of conflict of interest and funding statement
The corresponding author(s) of an article is asked to inform the Editor of the authors’ potential conflicts of interest possibly influencing the research or interpretation of data. Such conflicts may include financial support or private connections to pharmaceutical companies, political pressure from interest groups, or academic problems. A potential conflict of interest should be disclosed in the cover letter even when the authors are confident that their judgments have not been influenced in preparing the manuscript. In particular, all sources of funding for a study should be explicitly stated.

5) Data sharing and reproducibility

Data sharing policy: CIM follows the ICMJE Recommendations for data sharing statement policy (https://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html). As of July 1, 2018, manuscripts submitted to ICMJE journals that report the results of clinical trials must contain a data sharing statement. Authors are required to provide a data sharing statement indicating the following: whether individual deidentified participant data (including data dictionaries) will be shared (“undecided” is not an acceptable answer); what data in particular will be shared; whether additional, related documents will be available (e.g., study protocol, statistical analysis plan, etc.); when the data will become available and for how long; by what access criteria data will be shared (including with whom, for what types of analyses, and by what mechanism).

Registration of clinical trial research: Clinical trials are recommended to register with public repositories such as WHO International Clinical Trials Registry Platform (ICTRP, https://www.who.int/ictrp/en/), NIH ClinicalTrials.gov (https://www.clinicaltrials.gov/), ISRCTN Resistery (https://www.isrctn.com/), or Clinical Research Information Service (CRIS, https://cris.nih.go.kr/cris/index/index.do). If applicable, trial registration numbers should be included in the methods section. The registry should be publicly accessible (at no charge), open to all prospective registrants, and managed by a not-for-profit organization. For a list of registries that meet these requirements, please refer to the WHO ICTRP. Registration of all clinical trials facilitates information sharing among clinicians, researchers and patients, increases public confidence in research, and is consistent with ICMJE guidelines.

Access to data: If the study includes original data, at least one author must confirm that he or she had full access to all the data in the study, and takes responsibility for the integrity of the data and the accuracy of the data analysis. Authors are encouraged to share or make open the data supporting the results or analyses presented in their paper where this does not violate the protection of human subjects or other valid privacy or security concerns. Authors wishing to do so may deposit their data in a publicly accessible repository and include a link to the DOI within the text of the manuscript. Authors are further encouraged to cite any data sets referenced in the article and provide a Data Availability Statement.

6) Ethical oversight
CIM aims to ensure that all articles published in the journal report on work that is morally acceptable, and expects authors to follow the World Medical Association’s Declaration of Helsinki (https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/). All of the manuscripts should be prepared in strict observation of research and publication ethics guidelines recommended by the Council of Science Editors (CSE, https://www.councilscienceeditors.org/), International Committee of Medical Journal Editors (ICMJE, https://www.icmje.org/), World Association of Medical Editors (WAME, https://www.wame.org/), and the Korean Association of Medical Journal Editors (KAMJE, https://www.kamje.or.kr/board/view?b_name=bo_publication&bo_id=13&per_page=). Any study including human data must be reviewed and approved by a responsible Institutional Review Board (IRB). Animal experiments also should be reviewed by an appropriate committee for the care and use of animals (IACUC). Also studies with pathogens requiring a high degree of biosafety should pass review of a relevant committee (IBC). The editor may request submission of copies of informed consents from human subjects in clinical studies or IRB approval documents.

Informed consent and confidentiality: A statement of informed consent for human investigation should be made in the text, along with the name of the institutional review board that approved the study protocol. Authors must ensure that patient confidentiality is in no way breached. Do not use real names, initials, or disclose information that might identify a particular person without informed consent for publication.

Overlapping publication
Duplicate submission: All submitted manuscripts should be original and should not be considered by other scientific journals for publication at the same time. There should be no plagiarism or duplicate publication in the submitted manuscript. The fraudulent data should not be added to the manuscript. Any part of the accepted manuscript should not be duplicated in any other scientific journal without the permission of the Editorial Board.

Secondary publication: Secondary publication of material published in other journals or online may be justifiable and beneficial, especially when intended to disseminate important information to the widest possible audience (e.g., guidelines produced by government agencies and professional organizations in the same or a different language). Secondary publication for various other reasons may also be justifiable provided the conditions of the International Committee of Medical Journal Editors (ICMJE) Recommendations are met (https://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/overlapping-publications.html#four).

7) Intellectual property
All published papers become the permanent property of the Korean Academy of Sleep Medicine (KASMED). Copyrights of all published materials are owned by the KASMED.

8) Post-publication discussions and corrections
The post-publication discussion is available through the Correspondence. If any readers have a concern on any articles published, they can submit a Correspondence on the articles. If there founds any errors or mistakes in the article, it can be corrected through errata, corrigenda, or retraction. Corrections are reviewed by editors and authors, published promptly, and linked online to the original article. Regarding post-publication discussion, please contact the editorial office (editor@chronobiologyinmedicine.org).

8. Peer Review

All papers, including those invited by the Editor, are subject to peer review. If a manuscript does not fit the aims and scope of the Journal or does not adhere to the Instructions for Authors, it may be returned to the author immediately after receipt and without a review. A submitted manuscript will be acknowledged and assigned a manuscript number, which is to be used in all further correspondence. Before reviewing, all submitted manuscripts are inspected by Similarity Check powered by iThenticate (https://www.crossref.org/services/similarity-check/), a plagiarism-screening tool. Manuscripts are reviewed and given a priority based on their originality, importance of the findings, scientific merit and significance for the field, interest to readers, lucidity, and suitability for publication. Manuscripts with insufficient priority for publication are rejected promptly. Other manuscripts are sent to expert consultants for peer review. The journal uses a double-blind peer-review process such that the identities of both the reviewers and authors are kept confidential. The existence of a manuscript under review is not revealed to anyone other than peer reviewers and editorial staff. Peer reviewers are expected to maintain strict confidentiality. Reviewers are also expected to inform the Editor of any conflicts of interest, including any financial arrangements involving companies whose products (or competing products) are featured in the manuscripts they agree to review. Statistical editing may be done if the data needs professional statistical review by a statistician. After review, the editorial board determines whether or not the manuscript is accepted for publication. Once rejected, the manuscript is not subject to further review. Once the manuscript is received by the editorial board, an e-mail confirmation will be sent to the author within seven days. The author will be notified of any delays due to evaluation difficulties. Authors may contact the editorial committee for the current review phase of the manuscript. The board will inform the author of the status of the review process.

9. Access

CIM is an open-access journal. A free full-text service, both in XML and PDF formats, is available on the journal site immediately upon publication without an embargo period.

ORGANIZATION

10. Ownership and Management

Chronobiology in Medicine (official abbreviation: Chronobiol Med; CIM) is the official journal of the Korean Academy of Sleep Medicine (KASMED, https://www.sleep.or.kr/). The journal is managed by the Management Team (https://www.chronobiologyinmedicine.org/about/management.php).

11. Advisory Body

The advisory body is the journal's editorial board. The full names and affiliations of the journal’s editors are displayed on the Editorial Board tab (https://www.chronobiologyinmedicine.org/about/editorial.php) of the journal website.

12. Editorial Team and Contact Information

Editorial Office, Choronobiology in Medicine
Tel: +82-2-445-1611, Fax: +82-2-445-1633
E-mail: editor@chronobiologyinmedicine.org
Mailing address: RN1611, 8-13, Gwangpyeong-ro 56-gil, Gangnam-gu, Seoul 06367, Republic of Korea.

BUSINESS PRACTICES

13. Author Fees

There is no author-side submission fee or article processing charge. All publishing cost are supported by KASMED.

14. Other Revenue

Revenue sources of journal are from the support of publisher (Korean Academy of Sleep Medicine).

15. Advertising

CIM does not accept any commercial product advertisements until policy changes otherwise.

16. Direct Marketing

The journal was distributed through the journal's website and through the distribution of an introductory brochure. Invitations to submit a manuscript are usually sent to presenters at conferences, seminars or workshops if the topic is related to the aims and scope of the journal.